vimarsana.com

Page 29 - பல்கலைக்கழகம் ஆஃப் ஸிந்ஸந்யாடீ கல்லூரி மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biz Buzz Jan 10

The new outpatient medical director for Mind Springs Health, at 6916 Highway 82 in Glenwood Springs, brings years of experience to his new role. Dr. Frank James has dedicated his career to work on mental health disorders and opioid addiction. He’ll provide psychiatric services to child and adolescent patients at West Springs Hospital, at 515 28¾ Road in Grand Junction. Dr. James, an army veteran, has degrees from the University of Notre Dame and Southern Illinois University. He was a resident at the Walter Reed Army Medical Center in Maryland and also worked at The Children’s Hospital of Philadelphia and the University of Cincinnati College of Medicine.

Artificial Intelligence in Health Care

Artificial intelligence is transforming the health-care industry. From machine learning to robotics to wearable sensors used to detect disease, AI is reducing drug dosage errors, streamlining diagnosis, detecting fraud, and providing efficient solutions for some of health care’s greatest challenges. Washington Post Live will convene some of the nation’s top thinkers and innovators in the space who are overseeing the explosion of medical data analytics and machines that are transforming medical care as we know it, including in the fight against COVID-19. Join the conversation on Wednesday, Jan. 13.

Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol Cyclo in Patients with Niemann-Pick Disease Type C

Posted on 312 Cyclo Therapeutics, Inc. (NasdaqCM:CYTH) (NasdaqCM:CYTHW), a clinical stage biotechnology company developing a cyclodextrin platform for the treatment of neurodegenerative diseases, including its lead candidate Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC), today announced initial data from its “Open-Label Study of Long-Term Safety and Efficacy of Intravenous Trappsol ® Cyclo™ (HPBCD) in Niemann-Pick Disease Type C,” NCT03893071. Eight patients living in the US who completed the Phase I trial (NCT02939547) were eligible for the extension program. All eight enrolled. The first patient was dosed in the Open-Label extension study in May 2019 and the last patient enrolled was in February 2020. The initial efficacy results presented below have a data cut-off of September 2020.

WVXU: Meet UC doctor trying to change minds skeptical of COVID-19 vaccine

Date Time WVXU: Meet UC doctor trying to change minds skeptical of COVID-19 vaccine Louito Edje, MD, associate dean of graduate medical education at the University of Cincinnati College of Medicine and UC Medical Center, spoke with WVXU about why she is on a public relations blitz – she was featured in segments on CNBC, TMZ,BET and MSNBC – to change minds about vaccinations for COVID-19. The pandemic is having a disproportionate impact on Black Americans and Edje, a Black female physician, is hoping her participation in the Moderna vaccine trial and her voice may sway some opinions about vaccine safety and efficacy.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.